Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Accepted for publication May 27, 2019
- Published online April 1, 2020.
Article Versions
- Latest version (June 15, 2019 - 04:00).
- Latest version (November 15, 2019 - 04:00).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2020
Author Information
- Atul Deodhar⇑,
- Dafna D. Gladman,
- Iain B. McInnes,
- Sebastian Spindeldreher,
- Ruvie Martin,
- Luminita Pricop,
- Brian Porter,
- Jorge Safi Jr.,
- Abhijit Shete and
- Gerard Bruin
- From the Division of Arthritis & Rheumatic Diseases, Rheumatology Clinics, Oregon Health & Science University, Portland, Oregon, USA; Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Centre for Rheumatic Diseases, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK; PKS Bioanalytics, Novartis Institutes for Biomedical Research, Basel; Immunology and Dermatology, Novartis Pharma AG, Basel, Switzerland; Immunology and Dermatology, Novartis Pharmaceuticals Corp., East Hanover, New Jersey, USA.
- A. Deodhar, MD, Professor of Medicine, Division of Arthritis & Rheumatic Diseases, Rheumatology Clinics, Oregon Health & Science University; D.D. Gladman, MD, FRCPC, University Health Network, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; I.B. McInnes, MD, PhD, Centre for Rheumatic Diseases, Institute of Infection, Immunity and Inflammation, University of Glasgow; S. Spindeldreher, PhD, PKS Bioanalytics, Novartis Institutes for Biomedical Research; R. Martin, PhD, Immunology and Dermatology, Novartis Pharmaceuticals Corp.; L. Pricop, MD, Immunology and Dermatology, Novartis Pharmaceuticals Corp.; B. Porter, MD, PhD, MPH, MBA, Immunology and Dermatology, Novartis Pharmaceuticals Corp.; J. Safi Jr., MD, PhD, Immunology and Dermatology, Novartis Pharmaceuticals Corp.; A. Shete MD, Immunology and Dermatology, Novartis Pharma AG; G. Bruin, PhD, PKS Bioanalytics, Novartis Institutes for Biomedical Research.
- Address correspondence to Dr. A. Deodhar, Medical Director, Rheumatology Clinics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA. E-mail: deodhara{at}ohsu.edu
Article usage
In this issue
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
